Search & Analyze

Dr. Lal Pathlabs Ltd.

1,892.90−20.40 (−1.07%)

BSE · 30 Oct, 4:01 PM

: ₹31,997.02 Cr
: 59.05
: 59,842
: ₹1,956.90 - ₹1,892.90
: ₹2,035.00 - ₹1,272.00

Dr. Lal Pathlabs Ltd. (LALPATHLAB) share price closed at ₹1,892.90 on the BSE on Friday, October 30, 2026, down by 1.07% from its of ₹1,913.30. In that session LALPATHLAB reached a of 1,956.90 and of 1,892.90. The for the session was 1,926.53. The stands at 1,914.01 and is at 1,637.18. Looking at , the stock ended the session in Downtrend.

Stock Overview

₹1,902.25

₹1,913.30

₹1,926.53

₹1,914.01

Price 1.10% below

₹1,637.18

Price 15.62% above

Key Fundamentals

: 31,997.02 Cr₹32.00 Thousand Crore
: 32.29
: 59.05
: 12.25
: 155.67
: 942.80 Cr₹942.80 Crore
: 1.08 %
Sector
Industry: Hospital & Healthcare Services
: 22.37
: 0.00

Industry Comparison

Ratio	Company	Sector
	59.05	44.77
	0.00	0.20
	12.25	4.61
	3.48	1.81
	1.08 %	0.11 %
Operating Margin	28.32 %	19.15 %

Sector figures are the median of 154 listed Healthcare companies.

Peer Comparison

Name
APOLLO HOSP. APOLLOHOSP	8,400.00	57.80	1,20,779.11	0.24	610.40	38.41%	7,043.50	20.56%	21.73
MANIPALHOS MANIPALHOS	668.45	98.54	87,926.39	0.00	243.43	-4.18%	3,090.63	38.12%	13.93
MAXHEALTH MAXHEALTH	860.00	60.63	83,706.13	0.23	414.45	-15.64%	2,569.21	20.31%	14.97
ASTERDM ASTERDM	680.40	186.93	59,308.59	0.44	29.28	-68.70%	1,310.68	21.60%	16.22
FORTIS FORTIS	769.80	55.46	58,116.68	0.13	272.80	2.26%	2,545.03	17.46%	14.07
NH NH	1,700.00	43.06	34,741.34	0.26	301.15	16.50%	2,843.99	73.01%	16.20
MEDANTA MEDANTA	1,265.00	61.35	34,013.01	0.04	157.25	-1.09%	1,304.05	26.50%	19.38
Dr. Lal Pathlabs Ltd. LALPATHLAB	1,892.90	59.05	31,997.02	1.08	170.50	27.24%	797.70	19.10%	29.56

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	601.90	660.20	596.70	602.60	669.80	730.60	659.80	702.70	797.70
Expenses	431.90	457.70	442.70	433.60	477.50	506.50	480.50	515.90	550.20
	170.00	202.50	154.00	169.00	192.30	224.10	179.30	186.80	247.50
	28.24%	30.67%	25.81%	28.05%	28.71%	30.67%	27.17%	26.58%	31.03%
	20.60	21.90	25.10	25.80	28.10	24.80	-5.70	24.00	31.90
Interest	6.00	6.00	5.30	5.00	4.70	4.80	7.20	6.10	6.30
	34.70	35.30	35.50	36.40	34.60	40.50	42.10	44.60	44.40
	149.90	183.10	138.30	153.40	181.10	203.60	124.30	160.10	228.70
	28.09%	28.56%	29.07%	-1.37%	26.01%	25.25%	26.47%	17.43%	25.45%
	106.40	129.20	96.70	154.80	132.40	150.60	90.50	131.30	169.50
	12.74	15.45	11.57	18.52	15.80	17.97	5.40	7.83	10.11

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME:
Operating Income	2,087.41	2,016.88	2,226.64	2,461.40	2,762.91
Operating Income (Net)	2,087.41	2,016.88	2,226.64	2,461.40	2,762.91
EXPENDITURE :
Cost of Medicines and Consumables	502.25	447.15	451.42	481.46	534.62
Power & Fuel Cost	22.11	25.91	26.18	27.16	28.25
Employee Cost	364.94	376.52	424.57	455.78	503.26
Hospital Operation Expenses	361.63	385.55	423.24	468.05	530.86
Selling, Administration and Other Expenses	229.30	233.04	236.97	281.88	327.60
Miscellaneous Expenses	46.45	58.88	55.02	51.46	55.80
	1,526.68	1,527.05	1,617.40	1,765.80	1,980.40
Operating Profit (Excl OI)	560.73	489.83	609.24	695.60	782.52
	52.55	41.72	69.17	93.43	101.27
	613.27	531.55	678.41	789.03	883.78
Interest	30.18	37.53	29.36	22.31	22.80
PBDT	583.09	494.02	649.05	766.72	860.98
	108.11	150.19	143.60	141.92	161.80
Profit Before Taxation & Exceptional Items	474.98	343.83	505.45	624.80	699.18
Exceptional Income / Expenses					-30.09
	474.98	343.83	505.45	624.80	669.09
Provision for Tax	124.69	102.75	143.16	132.55	159.33
	350.29	241.08	362.29	492.25	509.75
Extra items		0.00	0.00	0.00	0.00
Minority Interest	-5.46	-2.23	-4.56	-5.11	-4.98
Consolidated Net Profit	344.83	238.85	357.74	487.14	504.78
Profit Balance B/F	981.85	1,209.69	1,418.70	1,576.64	1,859.96
Appropriations	1,326.69	1,448.53	1,776.43	2,063.78	2,364.74
Equity Dividend %	120.00%	120.00%	240.00%	240.00%	205.00%
	41.37	28.65	42.85	58.28	30.13
Adjusted EPS	20.69	14.32	21.43	29.14	30.13

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	83.35	83.37	83.48	83.59	167.56
Share Warrants & Outstandings	58.29	58.26	51.15	56.64	66.05
Total Reserves	1,359.98	1,524.67	1,714.66	2,032.48	2,274.53
Reserve excluding Revaluation Reserve	1,359.98	1,524.67	1,714.66	2,032.48	2,274.53
Revaluation reserve			0.00
	1,501.61	1,666.30	1,849.28	2,172.72	2,508.14
Minority Interest	35.46	33.25	36.08	33.76	33.14
Secured Loans	166.67	83.33
Unsecured Loans	0.13
Deferred Tax Assets / Liabilities	-33.00	-37.48	-42.47	-83.24	-81.51
Other Long Term Liabilities	138.86	129.99	103.02	102.64	145.42
Long Term Provisions			1.61	1.95	2.65
Total Non-Current Liabilities	272.66	175.84	62.16	21.34	66.56
Trade Payables	147.38	156.10	186.57	167.05	180.60
Other Current Liabilities	226.98	214.02	227.46	186.31	189.17
Short Term Borrowings	95.42	70.00
Short Term Provisions	30.20	29.63	49.55	48.99	80.85
Total Current Liabilities	499.99	469.75	463.58	402.35	450.62
Total Liabilities	2,309.71	2,345.14	2,411.10	2,630.17	3,058.46
Gross Block	1,726.23	1,807.22	1,828.44	1,903.54	2,146.43
Less: Accumulated Depreciation	357.42	502.16	634.62	768.56	922.86
	1,368.81	1,305.06	1,193.83	1,134.99	1,223.57
	14.45	2.97	3.95	3.48	5.49
Long Term Investment			0.00
Long Term Loans & Advances	39.89	35.21	31.26	26.66	33.32
Other Non Current Assets	10.86	26.84	19.97	68.18	195.76
Total Non-Current Assets	1,434.56	1,372.05	1,284.41	1,266.66	1,491.97
Currents Investments	65.46	149.94	113.78	326.70	422.59
Inventories	52.54	33.81	37.31	36.13	43.86
Sundry Debtors	85.40	70.82	77.40	88.12	110.69
Cash and Bank	617.59	665.41	830.31	838.68	909.54
Other Current Assets	33.83	34.38	47.89	50.89	53.37
Short Term Loans and Advances	20.34	18.72	20.01	23.00	26.45
Total Current Assets	875.15	973.09	1,126.70	1,363.51	1,566.49
Net Current Assets (Including Current Investments)	375.16	503.33	663.12	961.16	1,115.88
Total Assets	2,309.71	2,345.14	2,411.10	2,630.17	3,058.46
	13.18	13.64	10.09	10.59	16.76
Total Debt	345.65	236.67	83.33	0.00	0.00
	173.17	192.88	215.40	253.14	145.75
Adjusted Book Value	86.59	96.44	107.70	126.57	145.75

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	474.98	343.83	505.45	624.80	669.09
Adjustment	118.45	183.16	126.18	106.86	115.29
Changes In working Capital	-16.71	35.48	35.74	1.12	26.62
Cash Flow after changes in Working Capital	576.72	562.46	667.37	732.78	810.99
Cash Flow from Operating Activities	446.69	456.03	535.33	568.89	635.61
Cash Flow from Investing Activities	-449.25	-287.31	-24.27	-303.16	-421.86
Cash Flow from Financing Activitie	136.45	-283.18	-413.86	-334.03	-263.57
Net Cash Inflow / Outflow	133.90	-114.46	97.20	-68.31	-49.83
Opening Cash & Cash Equivalents	244.30	378.20	263.73	360.93	292.63
Closing Cash & Cash Equivalent	378.20	263.73	360.93	292.63	242.80

Ratios

Valuation

59.05

12.25

32.97

11.07

32.29

155.67

Profitability

22.37

29.56

17.92

28.32

18.45

Leverage & Liquidity

0.00

3.48

30.35

Returns

1.08

0.97

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26	Sep '26
	54.60	53.92	53.91	53.91	53.79	53.21	53.21	53.21	53.19	52.93
	38.13	39.71	39.99	39.99	39.47	40.20	39.36	38.43	38.82	40.16
	7.26	6.37	6.11	6.10	6.74	6.58	7.43	8.35	7.99	6.91
	45.40	46.08	46.09	46.09	46.21	46.79	46.79	46.79	46.81	47.07
No. of Shareholders	1,31,189	1,16,606	1,16,236	1,15,699	1,18,656	1,12,703	1,16,167	1,14,527	1,11,037	1,13,559

Mutual Funds Invested(161)

Based on each fund's latest monthly portfolio · Sep 2026

A total of 100 active funds hold 18.30% in Dr. Lal Pathlabs Ltd., contributing to ₹6.10K Cr of holdings

Fund				As of
HD HDFC Flexi Cap Fund - Growth - Direct PlanFlexi Cap Fund	830.26	0.76	41,78,451	Sep '26
UT UTI Flexi Cap Fund - Growth - Direct PlanFlexi Cap Fund	499.90	2.22	25,15,829	Sep '26
AB Aditya Birla Sun Life Flexi Cap Fund - Growth - Direct PlanFlexi Cap Fund	466.95	1.67	23,50,000	Sep '26
SB SBI Large & Midcap Fund - Growth - Direct PlanLarge & Mid Cap	258.31	0.64	13,00,000	Sep '26
NI Nippon India Small Cap Fund - Growth - Direct PlanSmall cap Fund	256.52	0.32	12,90,970	Sep '26
SU Sundaram Mid Cap Fund - Growth - Direct PlanMid Cap Fund	233.47	1.69	11,75,000	Sep '26
NI Nippon India Multi Cap Fund - Growth - Direct PlanMulti Cap Fund	227.81	0.42	11,46,484	Sep '26
HD HDFC ELSS - Tax Saver Fund - Growth - Direct PlanEquity - ELSS - Tax Saver Fund	226.52	1.52	11,40,000	Sep '26
NI Nippon India Pharma Fund - Growth - Direct PlanPharma & Health Care	198.81	2.17	10,00,578	Sep '26
HD HDFC Retirement Fund - Equity Plan - Growth - Direct PlanEquity Oriented	139.09	2.09	7,00,000	Sep '26

Corporate Actions

Showing: All

Date	Type	Details	Ex-Date	Record Date
2026-09-25	Board Meeting	Quarterly Results & Interim Dividend
2026-07-24	Ex Dividend	Rs.5.0000 per share(50%)Interim Dividend	2026-07-30	2026-07-30
2026-06-29	Board Meeting	Quarterly Results

Insider Trading

Date	Person	Category	Transaction Type	Shares
2026-09-30	Munender Soperna	ESOP	Buy	2,100
2026-09-30	Lal PathLabs Employee Welfare Trust	ESOP	Sell	4,050
2026-09-30	Abhishek Maini	ESOP	Buy	750
2026-09-30	Abhishek Maini	Market	Sell	750
2026-09-25	Sanjay Kulshreshtha	Market	Sell	1,500
2026-09-25	Mrinal Kapoor	ESOP	Buy	2,000
2026-09-25	Lal PathLabs Employee Welfare Trust	ESOP	Sell	3,000
2026-09-25	Mrinal Kapoor	Market	Sell	2,000
2026-09-25	Sanjay Kulshreshtha	ESOP	Buy	1,000
2026-09-21	Jai Prakash Meena	Market	Sell	4,500
2026-09-21	Nitish Rehal	ESOP	Buy	800
2026-09-21	Sanjay Kulshreshtha	ESOP	Buy	1,000
2026-09-21	Lal PathLabs Employee Welfare Trust	ESOP	Sell	2,350
2026-09-21	Nitish Rehal	Market	Sell	800
2026-09-15	Nitish Rehal	ESOP	Buy	400
2026-09-15	Nitish Rehal	Market	Sell	400
2026-09-15	Mrinal Kapoor	Market	Sell	2,000
2026-09-08	Sanjay Kulshreshtha	ESOP	Buy	500
2026-09-08	Lal PathLabs Employee Welfare Trust	ESOP	Sell	3,000
2026-09-08	Sanjay Kulshreshtha	Market	Sell	500

Sector Overview

HealthcareHospital & Healthcare Services

Dr. Lal Pathlabs Ltd. operates in the Healthcare sector under the Hospital & Healthcare Services industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

10 members across the board and senior leadership

Vinay Gujral

Company Secretary & Compliance Officer

—

Arvind Lal

Chairman

₹4.03 Cr

Mar '26

Vandana Lal

Whole Time Director

₹3.23 Cr

Mar '26

Arun Duggal

Non Executive Independent Director

₹98.50 L

Mar '26

Rajit Mehta

Non Executive Independent Director

₹49.00 L

Mar '26

Rohit Bhasin

Non Executive Independent Director

₹64.00 L

Mar '26

Somya Satsangi

Non Executive Independent Director

₹57.00 L

Mar '26

Archana Lal Erdmann

Promoter & Non-Executive Director

₹48.00 L

Mar '26

Rahul Sharma

Non Executive Director

₹53.00 L

Mar '26

Gurinder Singh Kalra

Non Executive Independent Director

₹44.50 L

Mar '25

LALPATHLAB Latest News

News

9 of 9 articles

EQUITY14 Oct 2026 · 14:20

Dr. Lal Pathlabs rises as its arm acquires remaining 30% stake in Centrapath Labs

Pursuant to the aforesaid acquisition, CPL has become a Wholly Owned Subsidiary of PUPL

COMPANY14 Oct 2026 · 14:11

Dr. Lal Pathlabs’ arm acquires remaining 30% stake in Centrapath Labs

Pursuant to the aforesaid acquisition, CPL has become a Wholly Owned Subsidiary of PUPL

EQUITY12 Oct 2026 · 17:43

Dr. Lal PathLabs informs about updates

COMPANY12 Oct 2026 · 15:30

Dr. Lal Pathlabs makes further investment in PathLabs Unifiers

The transaction value is not exceeding Rs 30.3 crore

COMPANY28 Sept 2026 · 12:20

Dr. Lal PathLabs’ arm completes acquisition of 80% stake in SHL, Ghana

Accordingly, SHL has become a step-down subsidiary of the company

COMPANY25 Sept 2026 · 12:29

Dr. Lal PathLabs gets nod to acquire 70% stake in SN Genelab

Post acquisition, SN Gene shall become a Subsidiary of the Company

COMPANY28 Aug 2026 · 11:14

Dr. Lal Pathlabs’ arm completes subscription of 30% stake in Neuome Technologies

Pursuant to completion of said subscription, Neuome has now become associate of the company

COMPANY20 Aug 2026 · 10:11

Dr. Lal Pathlabs’ arm incorporates subsidiary company in Uzbekistan

The objective of incorporation is to strengthen the group’s presence in Tashkent, Uzbekistan.

EQUITY2 Jul 2026 · 17:12

Dr. Lal PathLabs informs about newspaper publication

Dr. Lal Pathlabs Ltd.

Stock Overview

Price chart

Peer Comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Valuation

Profitability

Leverage & Liquidity

Returns

Shareholding Pattern

Mutual Funds Invested(161)

Corporate Actions

Insider Trading

Sector Overview

Company Profile

Key Management

LALPATHLAB Latest News

News